After Cingulate (CING) announced the termination of Laurie Myers as COO, Roth Capital caught up with Cingulate Therapeutics’ CEO Shane Schaffer to get additional clarity on the “sudden termination.” The firm’s conversation with the CEO suggests the COO’s departure has no meaningful impact on the company’s near-term strategy or long-term outlook, including the timelines for CTx-1301 FDA approval expected in mid-2026. Following the talks with the CEO, the firm reiterates its Buy rating and $11 price target on Cingulate shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate reports termination of Chief Operating Officer
- Cingulate Inc.’s Strategic Partnerships and NDA Submission Drive Buy Rating
- Cingulate Inc Submits NDA for ADHD Treatment
- Cingulate submits CTx-1301 NDA to FDA
- Cingulate Inc. Receives Buy Rating: PDUFA Fee Waiver and Competitive Edge of CTx-1301 Boost Market Prospects